SEC Form 4 · accession 0001209191-17-026344
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen K Doberstein
Officer — SVP & Chief Scientific Officer
Period of report
Apr 5, 2017
Accepted (ET)
Apr 7, 2017 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 5, 2017 | M | 100,000 | $9.53 | A | 134,504 | D | |
| Common StockF1,F2 | Apr 5, 2017 | S | 100,000 | $21.70 | D | 34,504 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $9.53 | Apr 5, 2017 | M | 100,000 | D | Jan 6, 2014 | Jan 5, 2018 | Common Stock | 100,000 | 440,000 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $21.07 to $22.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.